Figure 2.

In vitro characterization of citalopram and escitalopram following the in silico analyses against human cholinesterases and choline acetyltransferase. (A) Single 100 μM concentration screening for citalopram and escitalopram against human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). (B) Half-maximal inhibitory concentration (IC₅₀) assessment for citalopram at 0.5 and 5 mM concentrations of acetylthiocholine and butyrylthiocholine as substrates of AChE and BChE, respectively. (C) The corresponding IC₅₀ assessment for escitalopram against AChE and BChE. All data are shown as the percent of the enzymes’ activity in the presence of the solvent (vehicle control). Data are shown as mean ± SD. The IC₅₀ analyses were done with GraphPad Prism 9.